Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ernexa Therapeutics (ERNA) Interest Expenses (2022 - 2023)

Historic Interest Expenses for Ernexa Therapeutics (ERNA) over the last 2 years, with Q4 2023 value amounting to $245000.0.

  • Ernexa Therapeutics' Interest Expenses rose 12156.69% to $245000.0 in Q4 2023 from the same period last year, while for Sep 2024 it was $245000.0, marking a year-over-year increase of 13198.43%. This contributed to the annual value of $614000.0 for FY2023, which is 194666.67% up from last year.
  • As of Q4 2023, Ernexa Therapeutics' Interest Expenses stood at $245000.0, which was up 12156.69% from $114000.0 recorded in Q3 2023.
  • In the past 5 years, Ernexa Therapeutics' Interest Expenses registered a high of $256000.0 during Q2 2023, and its lowest value of -$1.1 million during Q4 2022.